Welcome to Firefly Marin

Marin’s licensed medical cannabis and cbd delivery service

Quality, Compassionate Care

At Firefly Marin our goal is to establish and provide the best customer service delivery with compassion and convenience. Our mission is to provide a safe alternative, natural way of healing without using industrialized pharmaceuticals or trips to the pharmacy.

Dr. Sanjay Gupta, MD Neurosurgeon & Chief Medical Correspondent states - “Every 19 Minutes somebody dies of prescription drug overdose. It doesn‘t happen with cannabis”

Cannabis and CBD Healing Naturally

We at Firefly offer a full spectrem of cannabis and CBD products geared to address a wide range of injuries, illnesses, insomnia, nausea and PTSD.

Our team of experienced professionals will guide you through your options to make sure that you are informed and comfortable with your selections.

Judge Frances L. Young, DEA Administrative Law Judge - “Cannabis in it‘s natural form is one of the safest therapeutically active substances known to man”

Our Promise to You

In order to provide our delivery clients with the highest level of care, our goal is to create an abundant top shelf menu of products that are 100% BCC compliant and lab tested at the highest level that will best suit all of your needs in the safest way possible.

Mitch Earlywine, PH.D

“Cannabis is a natural alternative to pharmaceutical pills”

Medical Cannabis Benefits

Chronic Pain

Patients who suffer from chronic pain caused by diabetes, cancer, MS, HIV, and other diseases have been turning to medical marijuana as a way to treat their pain without the use of addictive pharmaceutical medications.

Cancer

The active component of the marijuana plant, cannabinoids, have shown to inhibit tumor growth and kill cancer cells in lab testings. We work with a number of patients who use cannabis to treat their cancer and suppress it's side effects. giving them a better quality of life.

PTSD

There’s a study to support the use of cannabis to treat PTSD among returning US soldiers. The study is being led by Dr. Sue Sisley. It is part of the Multidisciplinary Association for Psychedelic Studies. The organization, called MAPS for short, is a research institute focused on exploring medicinal uses of cannabis and psychedelics.

Sisley’s project is focused specifically on learning how cannabis affects military veterans suffering from PTSD. The project first received approval from the U.S. Public Health Service in 2014.

Later that year, the Colorado Department of Public Health and Environment awarded a $2 million grant to complete the research.

Finally, in January 2017, research began at the Scottsdale Research Institute in Phoenix, Arizona. Now, a little over a year later, Sisley’s project is in its official Phase 2 clinical trial phase.

We at Firefly look forward to assisting our veterans upon there return and offer a 10% discount to all US veterans.

Thank you for your service.

TOP NEWS OF THE WEEK

Firefly CBD Now!!! Open with the best CBD products in Marin.

Firefly CBD is Now Open!!!

Firefly CBD is San Anselmo's first CBD retail storefront. We provide education and the best CBD products in Marin. Firefly CBD is located at 120 Greenfield Ave STE 124. Come in today and start feeling better tomorrow.

Americans Want CBD Sold Over-The-Counter, Gallup Poll Finds

A majority of Americans familiar with cannabidiol (CBD) say it should be available as an over-the-counter drug and believe that the compound has health benefits, according to a Gallup survey released June 14, 2019.

The CBD craze emerged from the marijuana reform movement and escalated following the passage of the 2018 Farm Bill, which federally legalized hemp and its derivatives including CBD. The survey, which involved 1,017 phone interviews conducted from May 15-30, offers some insight into the substance's widespread appeal.

Thirty-nine percent of Americans overall said that people should be able to access CBD as an over-the-counter drug, with 21 percent saying a prescription should be required. Thirty-six percent of respondents said they weren't familiar with the non-intoxicating compound.

But when Gallup asked people who said they were familiar with CBD the same question, 61 percent said that CBD should be sold over the counter and 33 percent said it should be available for those with a prescription.

Participants were also asked to rate their familiarity with CBD. Fourteen percent said they were very familiar, 33 percent said they were somewhat familiar, 17 percent said they were not too familiar, and 36 percent said they were not familiar at all.

Again, zeroing in on those who said they were familiar with CBD, Gallup asked what they thought about its therapeutic value.

Nine out of 10 respondents agreed that CBD does have health benefits. Breaking that down, 33 percent said it has a lot of benefits, 45 percent said it has some benefits and 14 percent said it has only a few benefits. Only four percent said it has no benefits and three percent didn't have an opinion.

“The CBD-oil arena is extremely active right now, including medical research into its benefits, state legislation governing its sale, federal legislation encouraging its production and corporate investment growing in the business,” Gallup wrote. “Although medical research has a long way to go to investigate all of the claims made about CBD, half of Americans already believe it has at least some medical value, and that percentage is likely to grow as more become familiar with the product.”

The commercial interest in CBD is explosive, with lawmakers and industry stakeholders putting pressure on federal agencies such as the Food and Drug Administration (FDA) to streamline the regulatory process to provide for the compound's lawful marketing in the food supply and as health supplements.

But even as the government develops those regulations, companies are wasting no time, flouting the FDA and putting CBD in drinks and foods such as pricey lattes and Carl's Jr. burgers. At the same time, CBD's medical value has been strongly established. The FDA approved a CBD drug, Epidiolex, in 2018 for the treatment of certain forms of epilepsy.

Gallup also released a separate survey June 13, 2019 that explored the various reasons Americans support or opposed broader marijuana legalization.